Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising data in preliminary clinical trials . Ongoing research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/